Today I’m delighted to welcome Andy Parker, CEO of Step Pharma.
With over 25 years of experience across AstraZeneca, Shire, Zealand Pharma, and venture capital, Andy has led Step Pharma since 2019. The company is pioneering a targeted approach to cancer and blood disorders by inhibiting the enzyme CTPS1. Their lead candidate, dencatistat, blocks this pathway that certain cancer cells and activated immune cells rely on, while sparing healthy cells that use the related CTPS2 enzyme.
In this episode, we’ll dive into the science behind this mechanism, explore Step Pharma’s expanding pipeline from lymphomas and solid tumours to essential thrombocythaemia, and discuss their recent €38 million Series C financing. We’ll also look ahead to the future of precision oncology.
01:17 Meet Andy Parker
06:12 The biotech ecosystem around Geneva
07:51 The CTPS1 enzyme and why cancer cells depend on it
14:08 Pipeline-in-a-product strategy across three indications
20:14 The series C: €38 million raise
25:41 Partnering with big pharma: possibilities and limits
28:11 The future of precision oncology and metabolic targeting
Podden och tillhörande omslagsbild på den här sidan tillhör
Labiotech. Innehållet i podden är skapat av Labiotech och inte av,
eller tillsammans med, Poddtoppen.
